Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Conditioning Regimen Before Stem Cell Transplant in AML and MDS
NCT02250937Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2014
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2014; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02250937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250937.